Last edition
News about Drug Discovery & Development
Thermo Fisher Scientific has announced an agreement to acquire Sanofi’s sterile fill-finish and packaging facility in Ridgefield, New Jersey, as part of a wider strategic partnership to strengthen drug product manufacturing in the United States. Financial details of the transaction remain undisclosed.
Drug Discovery & Development | 17/07/2025 | By Darshana | 365
The investigational therapy targets activating PI3Ka mutations, which are found in up to 40% of hormone receptor-positive (HR+)/HER2-negative advanced breast cancers and are implicated in a variety of solid tumors.
Drug Discovery & Development | 06/07/2025 | By Darshana | 234
CIPN is a common and often debilitating side effect of chemotherapy agents like platinum-based drugs, taxanes, and vinca alkaloids. It causes pain, tingling, and numbness in the extremities, potentially forcing dose reductions or treatment discontinuation, which can adversely impact patient outcomes.
Drug Discovery & Development | 03/07/2025 | By Darshana | 265
Moderna reports positive results from phase 3 efficacy study of P304 for seasonal influenza vaccine
In a previous phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine.
Drug Discovery & Development | 02/07/2025 | By Darshana | 294
Iksuda Therapeutics Secures FDA IND Clearance for IKS014
Iksuda Therapeutics has received FDA clearance for its IND application for IKS014, a HER2-targeting antibody drug conjugate, paving the way for US site participation in its ongoing Phase 1 trial for advanced HER2-positive solid tumours.
Drug Discovery & Development | 02/07/2025 | By Mrinmoy Dey | 198
Lupin receives US FDA approval for loteprednol etabonate ophthalmic gel
Loteprednol etabonate ophthalmic gel, 0.38% is bioequivalent to Lotemax SM ophthalmic gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin’s Pithampur facility in India.<br />
Drug Discovery & Development | 02/07/2025 | By Darshana | 230
Nona Biosciences has entered into a license agreement with Visterra, Inc. to accelerate the development of next-generation biotherapeutics for immune-mediated and autoimmune diseases using its proprietary HCAb Harbour Mice platform.
Drug Discovery & Development | 13/06/2025 | By Manvi | 145
NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies.
Drug Discovery & Development | 12/06/2025 | By Darshana | 210
Government Invites Fresh Applications Under PLI Scheme to Boost Bulk Drugs Production
Department of Pharmaceuticals has invited fresh applications under the performance-linked incentive (PLI) to boost bulk drug production. Focus will be on 11 key APIs, KSMs, and intermediates amid continued reliance on China. INR 6,940 crore outlay aims to strengthen domestic pharma manufacturing and reduce import dependency.
Drug Discovery & Development | 16/05/2025 | By Manvi | 588
STEERLife Redefines Potent Drug Development with Solvent-free Continuous Processing
STEERLife, the life sciences arm of STEER World, is transforming the development and manufacturing of complex and potent drug products through its proprietary solvent-free continuous processing technology.
Drug Discovery & Development | 15/05/2025 | By Manvi | 342
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy